AIRLINK 195.75 Increased By ▲ 0.92 (0.47%)
BOP 9.79 Decreased By ▼ -0.02 (-0.2%)
CNERGY 7.38 Increased By ▲ 0.02 (0.27%)
FCCL 40.35 Increased By ▲ 1.77 (4.59%)
FFL 16.37 Decreased By ▼ -0.08 (-0.49%)
FLYNG 28.74 Increased By ▲ 1.20 (4.36%)
HUBC 132.60 Increased By ▲ 0.85 (0.65%)
HUMNL 13.95 Increased By ▲ 0.09 (0.65%)
KEL 4.58 Decreased By ▼ -0.08 (-1.72%)
KOSM 6.70 Increased By ▲ 0.04 (0.6%)
MLCF 46.40 Increased By ▲ 1.01 (2.23%)
OGDC 214.69 Increased By ▲ 0.70 (0.33%)
PACE 6.84 Decreased By ▼ -0.02 (-0.29%)
PAEL 40.52 Increased By ▲ 0.46 (1.15%)
PIAHCLA 16.99 Increased By ▲ 0.20 (1.19%)
PIBTL 8.45 Increased By ▲ 0.13 (1.56%)
POWER 9.79 Increased By ▲ 0.36 (3.82%)
PPL 183.50 Increased By ▲ 1.31 (0.72%)
PRL 42.09 Increased By ▲ 0.26 (0.62%)
PTC 24.87 Increased By ▲ 0.31 (1.26%)
SEARL 103.99 Increased By ▲ 1.46 (1.42%)
SILK 1.00 No Change ▼ 0.00 (0%)
SSGC 39.80 Increased By ▲ 0.36 (0.91%)
SYM 17.31 Decreased By ▼ -0.02 (-0.12%)
TELE 8.78 Increased By ▲ 0.02 (0.23%)
TPLP 12.67 Decreased By ▼ -0.08 (-0.63%)
TRG 66.25 Increased By ▲ 0.85 (1.3%)
WAVESAPP 11.15 Increased By ▲ 0.04 (0.36%)
WTL 1.70 No Change ▼ 0.00 (0%)
YOUW 3.96 Increased By ▲ 0.02 (0.51%)
BR100 12,023 Increased By 48.7 (0.41%)
BR30 36,466 Increased By 319.8 (0.88%)
KSE100 113,659 Increased By 215.3 (0.19%)
KSE30 35,716 Increased By 81.2 (0.23%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published April 29, 2021

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed.